Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ATAI vs VOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VOR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–4 Matrix Metrics)

VOR Overall Winner 6-Pillar Tally: ATAI 1 – 4 VOR (1 Tie) Matrix Metrics: ATAI 4 – 4 VOR

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over ATAI Life Sciences N.V. Common Shares (ATAI) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ATAI carries a Unified Composite Score of 45.7/100 (HOLD) at $7.35 (N/M Forward P/E, -2590.4% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. ATAI 45.7/100 HOLD) and 1.90β · 61% Vol risk profile, whereas ATAI leads top-line expansion (+137.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATAI vs VOR
ATAI NASDAQ
ATAI Life Sciences N.V. Common Shares
Pharmaceutical Preparations
$7.35
+0.82% 1D
Market Cap $2.7B
TTM Revenue $4.5M
Forward P/E N/M
Beta / 30D Vol 1.13β · 10% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 34.0 Fund 47.0 Flow 59.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (21.6% over 20 days), RSI 61
RSI-14: 61.3 · SMA20: $7.34 · SMA50: $6.85
VOR NASDAQ Head-to-Head Winner
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.97
-2.32% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.90β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87

6-Pillar Scorecard Institutional Category Breakdown (ATAI 1 – 4 VOR)

Columns: Metric · ATAI · VOR
1. Valuation Multiples VOR
Forward P/E N/M N/M
Trailing P/E N/M 0.1x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ATAI
Revenue Growth (YoY) +137.0% +0.0%
Earnings Growth (YoY) -96.8% +0.0%
TTM Revenue (USD) $4.5M N/A
Market Cap $2.7B $1.2B
3. Profitability & Quality VOR
Gross Margin N/A N/A
Operating Margin -2590.4% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -417.2% -125.4%
4. Balance Sheet & Cash Flow VOR
Cash Generation (TTM) -$133M -$1.63B
Cash Flow Margin N/A N/A
Net Cash / Leverage $167M Net Cash $1.04B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 44.8% (38th %ile) 127.0% (6th %ile)
Put/Call OI Skew 0.76x (Call-Skewed) 2.03x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATAI (4) vs VOR (4)
Institutional Metric ATAI VOR Criterion Row Edge
Market Capitalization
Scale
$2.7B $1.2B Larger Scale ATAI
Trailing P/E Ratio
Valuation
N/M 0.1x Lower Multiple VOR
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+137.0% +0.0% Higher Growth ATAI
Operating Margin (TTM)
Profitability
-2590.4% 0.0% Higher Margin VOR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-417.2% -125.4% Higher ROE VOR
52-Week Range Position
Momentum
98% ($3–$7) 64% ($6–$26) Stronger Trend ATAI
Beta / 30D Volatility
Risk Regime
1.13β · 10% Vol 1.90β · 61% Vol Lower Realized Risk ATAI
Unified Institutional Score
Composite Signal
45.7 / 100 (HOLD) 57.8 / 100 (HOLD) Higher Composite VOR
Trailing 12M Revenue (USD)
Operating Scale
$4.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$133M ($167M Net Cash) -$1.63B ($1.04B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATAI +7.24 pp
ATAI: +1.94% · VOR: -5.3%
3M Horizon ATAI +22.59 pp
ATAI: +94.44% · VOR: +71.85%
6M Horizon ATAI +30.9 pp
ATAI: +81.03% · VOR: +50.13%
1Y Horizon VOR +51.16 pp
ATAI: +77.97% · VOR: +129.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATAI vs VOR. Trailing 12-month operating profitability (ATAI -2590.4% vs VOR 0.0%) and valuation multiples (ATAI N/M vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ATAI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.5M
Gross MarginN/A
Op. Margin-2590.4%
ROE / Fwd P/E-417.2% · N/M
VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATAI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 44.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.76x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATAI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 127.0%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATAI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.7B market capitalization and -2590.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATAI vs VOR Key Questions & Quantitative Answers

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over ATAI Life Sciences N.V. Common Shares (ATAI) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ATAI carries a Unified Composite Score of 45.7/100 (HOLD) at $7.35 (N/M Forward P/E, -2590.4% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. ATAI 45.7/100 HOLD) and 1.90β · 61% Vol risk profile, whereas ATAI leads top-line expansion (+137.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

ATAI leads the Growth & Scale pillar: ATAI posts +137.0% YoY revenue growth and -96.8% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -2590.4% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ATAI generates $4.5M in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, ATAI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.

VOR screens cheaper on headline valuation multiples. ATAI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATAI (-417.2% ROE) versus VOR (-125.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ATAI carries 44.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.76x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.13β · 10% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.90β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.